These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 32717614)

  • 1. The discovery and evaluation of 3-amino-2(1H)-pyrazinones as a novel series of selective p38α MAP kinase inhibitors.
    Raubo P; Evans R; Willis P
    Bioorg Med Chem Lett; 2020 Sep; 30(18):127412. PubMed ID: 32717614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial.
    Patel NR; Cunoosamy DM; Fagerås M; Taib Z; Asimus S; Hegelund-Myrbäck T; Lundin S; Pardali K; Kurian N; Ersdal E; Kristensson C; Korsback K; Palmér R; Brown MN; Greenaway S; Siew L; Clarke GW; Rennard SI; Make BJ; Wise RA; Jansson P
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1009-1019. PubMed ID: 29628759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The discovery of N-cyclopropyl-4-methyl-3-[6-(4-methylpiperazin-1-yl)-4-oxoquinazolin-3(4H)-yl]benzamide (AZD6703), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases.
    Brown DS; Cumming JG; Bethel P; Finlayson J; Gerhardt S; Nash I; Pauptit RA; Pike KG; Reid A; Snelson W; Swallow S; Thompson C
    Bioorg Med Chem Lett; 2012 Jun; 22(12):3879-83. PubMed ID: 22608965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological activity of 2H-quinolizin-2-one based p38alpha MAP kinase inhibitors.
    Tynebor RM; Chen MH; Natarajan SR; O'Neill EA; Thompson JE; Fitzgerald CE; O'Keefe SJ; Doherty JB
    Bioorg Med Chem Lett; 2010 May; 20(9):2765-9. PubMed ID: 20378346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and evaluation of 7-alkyl-1,5-bis-aryl-pyrazolopyridinones as highly potent, selective, and orally efficacious inhibitors of p38alpha mitogen-activated protein kinase.
    Pettus LH; Wurz RP; Xu S; Herberich B; Henkle B; Liu Q; McBride HJ; Mu S; Plant MH; Saris CJ; Sherman L; Wong LM; Chmait S; Lee MR; Mohr C; Hsieh F; Tasker AS
    J Med Chem; 2010 Apr; 53(7):2973-85. PubMed ID: 20218619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38α MAP kinase inhibitors.
    Dyckman AJ; Li T; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly KM; Shuster DJ; Doweyko AM; Sack JS; Kish K; Kiefer SE; Newitt JA; Zhang H; Marathe PH; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4633-7. PubMed ID: 21705217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Part 2: Structure-activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.
    Wurz RP; Pettus LH; Henkle B; Sherman L; Plant M; Miner K; McBride HJ; Wong LM; Saris CJ; Lee MR; Chmait S; Mohr C; Hsieh F; Tasker AS
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1680-4. PubMed ID: 20138761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biphenyl amide p38 kinase inhibitors 3: Improvement of cellular and in vivo activity.
    Angell R; Aston NM; Bamborough P; Buckton JB; Cockerill S; deBoeck SJ; Edwards CD; Holmes DS; Jones KL; Laine DI; Patel S; Smee PA; Smith KJ; Somers DO; Walker AL
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4428-32. PubMed ID: 18614366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Angle on MK2 Inhibition-Optimization and Evaluation of Prevention of Activation Inhibitors.
    Hedström U; Norberg M; Evertsson E; Lever SR; Munck Af Rosenschöld M; Lönn H; Bold P; Käck H; Berntsson P; Vinblad J; Liu J; Welinder A; Karlsson J; Snijder A; Pardali K; Andersson U; Davis AM; Mogemark M
    ChemMedChem; 2019 Oct; 14(19):1701-1709. PubMed ID: 31325352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel triazolopyridylbenzamides as potent and selective p38α inhibitors.
    Aiguadé J; Balagué C; Carranco I; Caturla F; Domínguez M; Eastwood P; Esteve C; González J; Lumeras W; Orellana A; Preciado S; Roca R; Vidal L; Vidal B
    Bioorg Med Chem Lett; 2012 May; 22(10):3431-6. PubMed ID: 22521646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological activity of pyridopyridazin-6-one p38 MAP kinase inhibitors. Part 1.
    Tynebor RM; Chen MH; Natarajan SR; O'Neill EA; Thompson JE; Fitzgerald CE; O'Keefe SJ; Doherty JB
    Bioorg Med Chem Lett; 2011 Jan; 21(1):411-6. PubMed ID: 21084192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Part 1: Structure-Activity Relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.
    Wurz RP; Pettus LH; Xu S; Henkle B; Sherman L; Plant M; Miner K; McBride H; Wong LM; Saris CJ; Lee MR; Chmait S; Mohr C; Hsieh F; Tasker AS
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4724-8. PubMed ID: 19574047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological activity of pyridopyridazin-6-one p38α MAP kinase inhibitors. Part 2.
    Tynebor RM; Chen MH; Natarajan SR; O'Neill EA; Thompson JE; Fitzgerald CE; O'Keefe SJ; Doherty JB
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5979-83. PubMed ID: 22901390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a potent p38α/MAPK14 kinase inhibitor: Synthesis, in vitro/in vivo biological evaluation, and docking studies.
    El-Gamal MI; Anbar HS; Tarazi H; Oh CH
    Eur J Med Chem; 2019 Dec; 183():111684. PubMed ID: 31520926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-amino-pyrazoles as potent and selective p38α inhibitors.
    Das J; Moquin RV; Dyckman AJ; Li T; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Newitt JA; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2010 Dec; 20(23):6886-9. PubMed ID: 21035336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of potent p38α MAPK inhibitors through a funnel like workflow combining in silico screening and in vitro validation.
    Astolfi A; Kudolo M; Brea J; Manni G; Manfroni G; Palazzotti D; Sabatini S; Cecchetti F; Felicetti T; Cannalire R; Massari S; Tabarrini O; Loza MI; Fallarino F; Cecchetti V; Laufer SA; Barreca ML
    Eur J Med Chem; 2019 Nov; 182():111624. PubMed ID: 31445234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of N-substituted pyridinones as potent and selective inhibitors of p38 kinase.
    Selness SR; Devraj RV; Monahan JB; Boehm TL; Walker JK; Devadas B; Durley RC; Kurumbail R; Shieh H; Xing L; Hepperle M; Rucker PV; Jerome KD; Benson AG; Marrufo LD; Madsen HM; Hitchcock J; Owen TJ; Christie L; Promo MA; Hickory BS; Alvira E; Naing W; Blevis-Bal R
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5851-6. PubMed ID: 19751974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.
    Pettus LH; Xu S; Cao GQ; Chakrabarti PP; Rzasa RM; Sham K; Wurz RP; Zhang D; Middleton S; Henkle B; Plant MH; Saris CJ; Sherman L; Wong LM; Powers DA; Tudor Y; Yu V; Lee MR; Syed R; Hsieh F; Tasker AS
    J Med Chem; 2008 Oct; 51(20):6280-92. PubMed ID: 18817364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and Toxicological Profiling of Aminopyridines as Orally Bioavailable Selective Inhibitors of PI3-Kinase γ.
    Bellenie BR; Hall E; Bruce I; Spendiff M; Culshaw A; McDonald S; Ambarkhane A; Chinn C; Thomas M; Rosner E; Bracher M; Nicklin P; Marshall S; Coote J; Cullen E; Tessier C; Wuersch K; Lal A; Wallis G; Hollingworth GJ; Neef J
    J Med Chem; 2021 Aug; 64(16):12304-12321. PubMed ID: 34384024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.